Stocks Health care BSX
NYSE · Health careBoston Scientific Corp (BSX)
Boston Scientific Corp brought in $21B of revenue over the twelve months to June 30, 2026, up 13.5% from a year earlier. Net income was $3.7B, a net margin of 17.5%. Operating cash flow minus capital spending left $3.7B of free cash flow in fiscal 2025. At June 30, 2026 it held $539M in cash against $10.9B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.
Key facts about Boston Scientific Corp
- Net worth
- Boston Scientific Corp has a market value (market cap) of $61.4B at the latest share price, and shareholders' equity of $24.9B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $20.1B (+19.9% year on year), with net income of $2.9B. Over the 12 months to June 30, 2026: revenue $21B, net income $3.7B.
- Cash flow
- In fiscal 2025 operations brought in $4.5B of cash; after $876M of capital spending, free cash flow was $3.7B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 3, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Boston Scientific Corp's next report is expected around October 26, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Boston Scientific Corp does
Boston Scientific develops, manufactures, and markets medical devices used in interventional medical specialties. Its products include pacemakers, defibrillators, stents, catheters, and endoscopy tools, which are purchased by hospitals, clinics, and physicians worldwide. Its shares trade on NYSE under the ticker BSX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $20.1B | $2.9B | $1.94 | $3.7B |
| 2024 | $16.7B | $1.9B | $1.25 | $2.6B |
| 2023 | $14.2B | $1.6B | $1.07 | $1.8B |
| 2022 | $12.7B | $642M | $0.45 | $938M |
| 2021 | $11.9B | $985M | $0.69 | $1.3B |
| 2020 | $9.9B | -$115M | -$0.08 | $1.1B |
Full financial statements: income, balance sheet and cash flow
Where BSX ranks in Health care
Dividends
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2024 | n/a | $0 | 0% |
| 2023 | n/a | $28M | 2% |
| 2022 | n/a | $55M | 9% |
| 2021 | n/a | $55M | 6% |
| 2020 | n/a | $28M | n/a |
| 2019 | n/a | $0 | 0% |
Latest SEC filings
What Boston Scientific Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 23, 2026Executive or director change8-KExecutive Vice President Arthur C. Butcher will retire from Boston Scientific Corporation effective January 1, 2027.
- September 8, 2026
- August 26, 2026Other event 8-K
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- August 3, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 7.5% to $5.4B versus the same quarter last year; diluted EPS $0.61 versus $0.53.
- July 29, 2026
- July 27, 2026
- June 24, 2026
- May 21, 2026
- May 18, 2026Other event 8-K
What is BSX worth? A DCF from its reported cash flow
Insider trades
What the people running Boston Scientific Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $9.5M worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 2, 2026 | O'Connor Padraig AndrewEVP, Global Operations | Exercised options | 1,171 | - |
| September 2, 2026 | O'Connor Padraig AndrewEVP, Global Operations | Shares withheld for tax | 567 | $27.4K |
| August 25, 2026 | Morano Susan EDirector | Bought | 2,040 | $100.4K |
| August 11, 2026 | Woodworth EmilySVP, Global Controller and CAO | Other changeindirect | 2,930 | $150K |
| August 10, 2026 | Monson JonathanEVP and CFO | Other changeindirect | 9,908 | $500K |
| August 5, 2026 | Habiger David CDirector | Bought | 2,100 | $99.9K |
| August 4, 2026 | Habiger David CDirector | Bought | 140 | $6.8K |
| August 3, 2026 | Mahoney Michael FChairman, President & CEO, Director | Bought | 186,240 | $9M |
Who owns BSX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.47% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 1,474 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 129,680,916 | -2,141,121 |
| Vanguard Capital Management LLC | 97,087,553 | +675,985 |
| State Street Corp | 70,111,196 | +2,124,349 |
| Primecap Management Co | 50,520,914 | +17,991,140 |
| Fmr LLC | 45,702,845 | -28,523,550 |
| Massachusetts Financial Services Co | 24,859,191 | +13,862,619 |
| Geode Capital Management, LLC | 33,440,102 | +154,345 |
| Vanguard Portfolio Management LLC | 29,792,794 | -3,417 |
| D. E. Shaw & Co., Inc. | 25,457,409 | +1,145,057 |
| Jpmorgan Chase & Co | 23,907,838 | -9,442,319 |
| Arrowstreet Capital, Limited Partnership | 23,293,913 | +9,402,245 |
| Norges Bank | 21,170,029 | new |
| Two Sigma Investments, LP | 19,359,023 | +9,947,792 |
| Morgan Stanley | 18,947,147 | -3,319,517 |
| Jupiter Topco LLC | 18,822,853 | new |
| Goldman Sachs Group Inc | 16,954,342 | -1,937,282 |
| Capital World Investors | 16,812,257 | +1,502,519 |
| UBS Group AG | 16,352,420 | +1,527,758 |
| Wellington Management Group Llp | 15,301,828 | -3,531,578 |
| Amundi | 14,296,121 | +173,208 |
Insiders
16 insiders reported holding 2,253,748 shares in total, about $95.6M at the last price.
| Holder | Shares |
|---|---|
| Mahoney Michael FChairman, President & CEO, Director | 1,612,14322,119 held indirectly |
| Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology | 278,10564,198 held indirectly |
| Butcher Arthur CEVP& Grp Pres, MedSurg & APAC | 77,09220,205 held indirectly |
| Brown Vance REVP, GC and Corp. Secretary | 54,244 |
| Monson JonathanEVP and CFO | 48,9719,908 held indirectly |
| Wichmann David SDirector | 45,382 |
| Ludwig Edward JDirector | 30,359 |
| Zane Ellen MDirector | 27,934 |
| O'Sullivan MiriamSVP, Chief HR Officer | 17,302 |
| Habiger David CDirector | 17,160 |
Questions about BSX
What does Boston Scientific Corp do?
Boston Scientific develops, manufactures, and markets medical devices used in interventional medical specialties. Its products include pacemakers, defibrillators, stents, catheters, and endoscopy tools, which are purchased by hospitals, clinics, and physicians worldwide. Its shares trade on NYSE under the ticker BSX.
What is Boston Scientific Corp's net worth?
Boston Scientific Corp has a market value (market cap) of $61.4B at the latest share price, and shareholders' equity of $24.9B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Boston Scientific Corp profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $3.7B on revenue of $21B, a net margin of 17.5%.
How much revenue does Boston Scientific Corp make?
Over the twelve months to June 30, 2026 Boston Scientific Corp reported revenue of $21B. That is 13.5% more than a year earlier.
When did Boston Scientific Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from September 23, 2026.
When is Boston Scientific Corp's next earnings report?
Boston Scientific Corp's next report is expected around October 26, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BSX with
Follow BSX
Get an email when Boston Scientific Corp files with the SEC: results, executive changes, material agreements and annual reports.
Follow BSX: get an email when it filesWhere the numbers come from
Financial figures are the values Boston Scientific Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.